Literature DB >> 20843259

LNK mutations in JAK2 mutation-negative erythrocytosis.

Terra L Lasho, Animesh Pardanani, Ayalew Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20843259     DOI： 10.1056/NEJMc1006966

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  44 in total

1.  Recurring mutations in myeloproliferative neoplasms alter epigenetic regulation of gene expression.

Authors:  Gary W Reuther
Journal:  Am J Cancer Res       Date:  2011-05-29       Impact factor: 6.166

Review 2.  Genomic profiling of B-progenitor acute lymphoblastic leukemia.

Authors:  Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2011-11-06       Impact factor: 3.020

Review 3.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes; Srdan Verstovsek
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

4.  Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis.

Authors:  Ambra Spolverini; Lisa Pieri; Paola Guglielmelli; Alessandro Pancrazzi; Tiziana Fanelli; Chiara Paoli; Alberto Bosi; Ilaria Nichele; Marco Ruggeri; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

Review 5.  Normal and malignant megakaryopoiesis.

Authors:  Qiang Wen; Benjamin Goldenson; John D Crispino
Journal:  Expert Rev Mol Med       Date:  2011-10-21       Impact factor: 5.600

6.  Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.

Authors:  Ayalew Tefferi; Pierre Noel; Curtis A Hanson
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

7.  JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.

Authors:  Alessandro M Vannucchi; Lisa Pieri; Paola Guglielmelli
Journal:  Ther Adv Hematol       Date:  2011-02

Review 8.  12q24 locus association with type 1 diabetes: SH2B3 or ATXN2?

Authors:  Georg Auburger; Suzana Gispert; Suna Lahut; Ozgür Omür; Ewa Damrath; Melanie Heck; Nazlı Başak
Journal:  World J Diabetes       Date:  2014-06-15

9.  Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

Authors:  Mohamad Bassam Sonbol; Belal Firwana; Ahmad Zarzour; Mohammad Morad; Vishal Rana; Ramon V Tiu
Journal:  Ther Adv Hematol       Date:  2013-02

Review 10.  Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.

Authors:  Brady L Stein; Stephen T Oh; Dmitriy Berenzon; Gabriela S Hobbs; Marina Kremyanskaya; Raajit K Rampal; Camille N Abboud; Kenneth Adler; Mark L Heaney; Elias J Jabbour; Rami S Komrokji; Alison R Moliterno; Ellen K Ritchie; Lawrence Rice; John Mascarenhas; Ronald Hoffman
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.